# Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

> **NCT04852081** · — · UNKNOWN · sponsor: **Blokhin's Russian Cancer Research Center** · enrollment: 1000 (estimated)

## Conditions studied

- Breast Cancer Stage IV

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Ribociclib
- **DRUG:** Abemaciclib
- **DRUG:** Letrozole
- **DRUG:** Anastrozole
- **DRUG:** Tamoxifen
- **DRUG:** Fulvestrant
- **DRUG:** Exemestane
- **DRUG:** Alpelisib

## Key facts

- **NCT ID:** NCT04852081
- **Lead sponsor:** Blokhin's Russian Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2021-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04852081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04852081, "Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04852081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*